Tags : Inflammatory

AbbVie Signs an Exclusive Research and Option to License Agreement

Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund […]Read More

Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory

Shots: The EMA’s CHMP has recommended marketing authorization of Amsparity, a biosimilar referencing AbbVie’s Humira Amsparity will be available in a 40 mg pre-filled syringe and pre-filled pen for adults and a 20 mg pre-filled syringe and 40 mg/0.8 mL vial for children. Amsparity showed high bio-similarity data in terms of quality, safety and efficacy […]Read More

Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors

Shots: Genentech to acquire Jecure, in all stock transaction for the portfolio of preclinical NLRP3 inhibitors The acquisition is focus to develop therapies using Jecure’s NLRP3 inhibitors for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis NLRP3 – Nucleotide-binding oligomerization (NOD)-like Receptor Family Pyrin Domain Containing Protein3, investigated for the treatment of autoimmune and […]Read More